 TORONTO, ON ACCESSWIRE March 15, 2021 Edesa Biotech, Inc. NASDAQ:EDSA, a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it has completed enrollment of more than 50 of the patients planned for the Phase 2 portion of its ongoing Phase 2Phase 3 clinical study evaluating the companys EB05 drug candidate as a single-dose treatment for hospitalized COVID-19 patients with or at risk of developing Acute Respiratory Distress Syndrome ARDS - the leading cause of death in COVID-19 patients. The company reported that more than 160 of the expected 316 subjects in the Phase 2 portion of the study have been randomized and dosed with either EB05 or placebo. 